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ABSTRACT
The interplay effects of matrix formulations with microwave on drug release were
investigated using an agglomerate system. Chitosan spheroids were formulated with
stearic acid and/or sodium chloride by extrusion-spheronization technique, and
chlorpheniramine maleate as water-soluble model drug. The spheroids were treated
by microwave at 80 W for 5 to 40 min. The profiles of drug dissolution, drug
content, drug-polymer interaction, polymer-polymer interaction, sodium leaching,
matrix morphology and integrity were determined. Unlike chitosan matrix prepared
by ionotropic gelation method, the retardation of drug release from chitosan
spheroids by microwave required a more complex formulation containing both
stearic acid and sodium chloride unless a high stearic acid fraction was used. These
spheroids demonstrated a high resistance to disintegration during dissolution owing
to salt-induced bridging by sodium chloride. In response to microwave, sodium
chloride aided stearic acid spread and effected domain interaction via C=O moiety
over a matrix with reduced specific surface area thereby reducing drug dissolution.
The drug release of spheroids can be retarded by microwave through promoting the
layering of hydrophobic stearic acid in a matrix structure sustained by sodium
chloride.
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CHAPTERl
INTRODUCTION
1.1 Background of the Research
The main interest of this research is to formulate chitosan spheroids prepared
via extrusion-spheronization technique with controlled characteristics with respect to
drug release. The controlled-release characteristics of chitosan spheroids can be
achieved via modulating the physicochemical properties of spheroids using new
formulation strategy and microwave technology.
Controlled-release technology has been rapidly developed over the past three
decades as a new interdisciplinary science that offers novel approaches to the
delivery of bioactive agents into systemic circulation at a predetermined rate (Kim,
2000; Aulton, 2002). The development of controlled-release technology is aimed to
eliminate the limitations of conventional dosage forms whereby repetitive
administration of conventional dosage forms leads to fluctuations of drug
concentration in plasma and site of action over successive dosing intervals and hence
not possible to maintain a constant therapeutic concentration of drug at site of
treatment. The unavoidable fluctuations of drug concentration in plasma and at site of
action can result in patient being overmedicated or undermedicated. In addition, the
need of patient for frequent administration of conventional dosage forms is
accompanied by reduced patience compliance which forms the main reason for
therapeutic inefficiency or failure.
The development of controlled-release dosage form is translated to reduce
frequency in drug administration and fluctuation in therapeutic plasma drug
concentration (Aulton, 2002; Razem, 2008). Constant therapeutic plasma drug
